Distinct cytokine profiles associated with COVID-19 severity and mortality

Karim Dorgham, PhD,* Paul Quentric, MD, MSc,* Mehmet Gökayka, MSc,b,c,* Christophe Parizot, MSc,a,c Delphine Sauce, PhD,b,* Amélie Guihot, MD, PhD,a,* Charles-Edouard Luyt, MD, PhD,f,q Matthieu Schmidt, MD, PhD, Julien Mayaux, MD, Chloé Marot, MD, Paris, MD; Paul Quentric, MD, MSc, a* Mehmet Gökayka, MSc, b,c,* Stephane Marot, MD, d Sophie Demeret, MD, Elyes Ben Salah, PharmD, MSc,a,c,* Alexis Mathian, MD, PhD,a,k Hans Yssel, PhD,a Béhazine Combadiere, PhD,a Christophe Combadiere, PhD,a Claudia Traidl-Hoffmann, MD, PhD, b,c,l Sonia Burrel, PharmD, PhD, d Anne-Geneviève Marcellin, PharmD, PhD, d Zahir Amoura, MD, PhD,a,k Guillaume Voiriot, MD, m Avidan U. Neumann, PhD, b,c,n and Guy Gorochov, MD, PhD,a,e Paris, France; Augsburg, Germany; Davos, Switzerland; and Prague, Czech Republic

GRAPHICAL ABSTRACT

From *Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses, CMI-Paris, Paris; †the Department of Environmental Medicine, Faculty of Medicine, University Hospital of Augsburg, Augsburg; ‡the Institute of Environmental Medicine (IEM), Technical University of Munich and Helmholtz Zentrum München, Augsburg; †Sorbonne Université, Inserm, Institut Pierre Louis d’Épidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département de Virologie, Paris; ‡AP-HP, Hôpital Pitié-Salpêtrière, Département d’Immunologie, Paris; †AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Institut de Cardiologie, Paris; †Sorbonne Université, Inserm, Institute of Cardiometabolism and Nutrition (ICAN), Paris; ‡AP-HP, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive - Réanimation, Paris; †Sorbonne Université, Inserm UMR S 1158, Neurophysiologie respiratoire expérimentale et clinique, Paris; †Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Département de Neurologie, Unité de Médecine Intensive et Réanimation Neurologique, Paris; ‡AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne 2, Institut EJM, Paris; †Christine Kühne Center for Allergy Research and Education (CK-CARE), Davos; †AP-HP, Hôpital Tenon, Service de Médecine Intensive Réanimation, Paris; and †the Institute of Experimental Medicine (IEM), Czech Academy of Sciences, Prague.

*These authors contributed equally to this work.
†These authors contributed equally to this work.

This study was supported by the Fondation de France, “Tous unis contre le virus” framework Alliance (Fondation de France, AP-HP, Institut Pasteur) in collaboration with Agence Nationale de la Recherche (ANR Flash COVID19 program), by the SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University ICOViD programs, by the Programme Hospitalier de Recherche Clinique PHRC-20-0375 COVID-19 (PI: G.G.), by the Christine Kühne - Center for Allergy Research and Education (M.G., C.T.-H., and A.U.N.), and by the Initiative and Networking Fund (Immunology & Inflammation) of the Helmholtz Association (M.G., C.T.-H., and A.U.N.).

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication November 10, 2020; revised February 20, 2021; accepted for publication March 25, 2021.

Available online April 22, 2021.

Corresponding author: Guy Gorochov, MD, PhD, Département d’Immunologie, Hôpital Pitié-Salpêtrière, 83 bd. de l’Hôpital, 75013 Paris, France. E-mail: guy.gorochov@sorbonne-universite.fr.

The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections 0991-6749/$36.00 © 2021 American Academy of Allergy, Asthma & Immunology https://doi.org/10.1016/j.jaci.2021.03.047
Background: Markedly elevated levels of proinflammatory cytokines and defective type-I interferon responses were reported in patients with coronavirus disease 2019 (COVID-19). Objective: We sought to determine whether particular cytokine profiles are associated with COVID-19 severity and mortality. Methods: Cytokine concentrations and severe acute respiratory syndrome coronavirus 2 antigen were measured at hospital admission in serum of symptomatic patients with COVID-19 (N = 115), classified at hospitalization into 3 respiratory severity groups: no need for mechanical ventilatory support (No-MVS), intermediate severity requiring mechanical ventilatory support (MVS), and critical severity requiring extracorporeal membrane oxygenation (ECMO). Principal-component analysis was used to characterize cytokine profiles associated with severity and mortality. The results were thereafter confirmed in an independent validation cohort (N = 86).

Results: At time of hospitalization, ECMO patients presented a dominant proinflammatory response with elevated levels of TNF-α, IL-6, IL-8, and IL-10. In contrast, an elevated type-I interferon response involving IFN-α and IFN-β was characteristic of No-MVS patients, whereas MVS patients exhibited both profiles. Mortality at 1 month was associated with higher levels of proinflammatory cytokines in ECMO patients, higher levels of type-I interferons in No-MVS patients, and their combination in MVS patients, resulting in a combined mortality prediction accuracy of 88.5% (risk ratio, 24.3; P < .0001). Severe acute respiratory syndrome coronavirus 2 antigen levels correlated with type-I interferon levels and were associated with mortality, but not with proinflammatory response or severity.

Conclusions: Distinct cytokine profiles are observed in association with COVID-19 severity and are differentially predictive of mortality according to oxygen support modalities. These results warrant personalized treatment of COVID-19 patients based on cytokine profiling. (J Allergy Clin Immunol 2021;147:2098-107.)

Key words: COVID-19, serum cytokines, type-I interferons, respiratory severity, mortality, principal-component analysis

Coronavirus disease 2019 (COVID-19) is a recently emerged global infectious respiratory disease that is caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), a novel betacoronavirus. Interindividual clinical variability over the course of SARS-CoV-2 infection is notorious, and prognosis remains difficult to predict at hospital entry. Respiratory failure is the most prominent feature associated with severe COVID-19, but severe damage to other organs is also observed. Many treatments have been tried to date, albeit with mixed results, which might be linked with the clinical and biological heterogeneity of the disease.

COVID-19 has been associated with the onset of a “cytokine storm,” an abnormal regulation and exuberant release of several proinflammatory cytokines at inappropriate time intervals during infection. It remains however unclear whether all patients present with the same type of cytokine release syndrome. We therefore postulated that focusing on separate cytokine levels might give only a partial view of a complex and interlinked inflammatory response that might not account for the various clinical profiles associated with COVID-19.

In the present study, we used highly sensitive, classical or digital, multiplex ELISA technologies to analyze combined cytokine production profiles in serum of patients with COVID-19 at the time of hospital admission. Thereafter, we used a nonsupervised bioinformatics approach to identify the cytokine combinations that represent a reliable biomarker of COVID-19–related pulmonary severity and/or mortality.

METHODS
Patients and samples
This prospective study was performed at Pitie–Salpetriere Hospital in Paris and approved by the local ethical committee, Comité d’Ethique de la Recherche (CER-SU), of Sorbonne University (CER-2020-21 and -31). Patients with real-time RT-PCR–confirmed SARS-CoV-2 RNA presence in their nasopharyngeal swab, and pulmonary manifestations, were included after admission to intensive care units or to the Internal Medicine department.

A total of 115 patients with COVID-19 (demographic and clinical characteristics in Table I and Table E1 in this article’s Online Repository at www.jacionline.org) were enrolled between March 17 and May 11, 2020, in the initial cohort. Patients were divided at day of hospitalization into 3 groups according to severity of pulmonary involvement: (1) moderate severity treated with no oxygen support, nasal cannula, or oxygen mask (No-MVS, N = 34), (2) intermediate severity requiring mechanical ventilatory support (MVS, N = 50), and (3) critical respiratory failure requiring extracorporeal membrane oxygenation (ECMO, N = 31). At 1 month after admission, 7 (20.6%), 19 (38%), and 7 (22.6%) patients were deceased in the No-MVS, MVS, and ECMO groups, respectively. In addition, healthy SARS-CoV-2–negative individuals (N = 10) were included as controls.

A validation cohort included 86 patients with COVID-19 (clinical characteristics in Table E2 in this article’s Online Repository at www.jacionline.org) enrolled between June 28 and November 23, 2020. Patients were classified into respiratory severity groups as in the initial cohort (No-MVS: N = 10, MVS: N = 58, and ECMO: N = 18). New therapeutic guidelines led to a decrease in mortality: No-MVS: 0 (0%), MVS: 16 (27.6%), and ECMO: 4 (22.2%). In particular, all patients in the validation cohort received glucocorticoid treatment.

Serum samples in the initial cohort were all collected at the day of hospital admission. However, in the validation cohort, samples were collected over the first 2 weeks after hospitalization (median, 5 days). Only patients with sample collected at most 21 days after symptom onset were included in the analysis (median, 9 and 12 days in initial and validation cohorts, respectively).

Immunoassays
Serum cytokine concentrations were determined using the Quanterix platforms (IFN-α, IFN-γ, IL-1β, IL-6, IL-8, IL-10, IL-17A, IL-18, IL-22, GM-CSF, and TNF-α) and ELISA (IFN-β) from PBL Assay Science.

Serum nucleocapsid (N) antigen concentrations were determined using the COV-QUANTO ELISA kit (AAZ, Boulogne Billancourt, France).

Procedures and specificity of the immunoassays used in this work are detailed in this article’s Methods section in the Online Repository at www.jacionline.org.
TABLE I. Demographic characteristics, baseline features, and clinical outcomes of 115 patients with COVID-19 in the initial cohort

| Characteristic                        | No-MVS (N = 34) | MVS (N = 50) | ECMO support (N = 31) | All patients (N = 115) | P value* |
|---------------------------------------|-----------------|--------------|-----------------------|------------------------|----------|
| Age (y), median (IQR)                 | 73 (46-73)      | 63 (55-69)   | 49.5 (42-56)          | 58 (49-66)             | <.001    |
| Sex: male, n (%)                      | 22 (64.7)       | 36 (72)      | 25 (83.3)             | 33 (72.2)              | .36      |
| Severity score at baseline            |                 |              |                       |                        |          |
| SAPS-II, median (IQR)                 | 26 (18-33)      | 35 (27-44)   | 52 (45-65)            | 36 (26-49)             | <.001    |
| SOFA, median (IQR)                    | —               | 7 (4-7)      | 12 (9-15)             | —                      | <.001    |
| Respiratory severity                  |                 |              |                       |                        |          |
| Nasal cannula or high-concentration   | 25 (73.5)       | —            | —                     | 25 (21.7)              |          |
| Noninvasive ventilation or high-flow  | —               | 10 (20)      | —                     | 10 (8.7)               |          |
| Invasive mechanical ventilation       | —               | 40 (80)      | 31 (100)              | 71 (61.7)              |          |
| ECMO                                  | —               | —            | 31 (100)              | 31 (27)                |          |
| Time from onset of symptoms to        |                 |              |                       |                        |          |
| admission/sample                      | 8 (2-11)        | 9 (7-11)     | 12 (8-15)             | 9 (6-12)               | .001     |
| Past medical history, n (%)           |                 |              |                       |                        |          |
| Cardiovascular disease                | 11 (32.4)       | 10 (20)      | 2 (6.5)               | 23 (20)                | .03      |
| Type 2 diabetes                       | 11 (32.4)       | 19 (38)      | 12 (38.7)             | 42 (36.5)              | .83      |
| Obesity (≥20)                         | 7 (20.6)        | 18 (36)      | 19 (61.3)             | 44 (38.3)              | .03      |
| Hypertension                          | 19 (55.9)       | 29 (58)      | 17 (54.8)             | 45 (36.5)              | .96      |
| Any condition                         | 28 (82.4)       | 41 (82)      | 28 (90.3)             | 97 (84.3)              | .57      |
| Clinical outcome at 1 mo (%)          |                 |              |                       |                        |          |
| Discharged                            | 27 (79.4)       | 30 (60)      | 20 (64.5)             | 77 (67)                | .17      |
| Remained in hospital                  | 0 (0)           | 1 (2)        | 4 (12.9)              | 5 (4.3)                | .25      |
| Deceased                              | 7 (20.6)        | 19 (38)      | 7 (22.6)†             | 33 (28.7)              | .23      |
| Length of stay§ (d), median (IQR)     | 10 (6-16)       | 10 (7-22)    | 32 (25-55)            | 13 (7-29)              | <.001    |

SAPS, Simplified Acute Physiology Score. SOFA, Sequential Organ Failure Assessment. Boldface values indicate statistical significant differences between the groups.

*Kruskal-Wallis test for continuous variables; Fisher exact test for discrete variables.
†Including hypertension, diabetes, obesity, cancer, arterial thromboembolism, venous thromboembolism, systemic autoimmune disease, HIV infection, solid organ transplant, chronic pulmonary disease, chronic liver disease, chronic kidney disease, chronic neurologic disease, and cardiovascular disease.
‡Two additional patients died later than day 30 of hospitalization (at day 46 and day 50).
§As of June 18, 2020.

Statistical and bioinformatics analysis
Principal-component analysis (PCA) was used to determine the cytokine combinations associated with severity and mortality. Statistical significance of differences between groups was assessed using the nonparametric Mann-Whitney and Kruskal-Wallis tests for continuous variables and Fisher exact test for frequencies. Correlations were assessed by the nonparametric Spearman test. Analyses were performed with SPSS, GraphPad-Prism, and R. Two-sided P value less than .05 was considered statistically significant (ns: nonsignificant; *P < .05; **P < .01; ***P < .001; ****P < .0001).

For detailed methods, please see this article’s Methods section in the Online Repository.

RESULTS
Patients’ severity and mortality
Patients with COVID-19 in the initial cohort (N = 115) were classified into 3 respiratory severity groups: no need for mechanical ventilatory support (No-MVS), intermediate severity requiring MVS, and critical severity requiring extracorporeal membrane oxygenation (ECMO). Mortality at 1 month after admission (28.7%) was not different between the 3 severity groups (P = .23). The Simplified Acute Physiology Score (SAPS-II: median, 36; interquartile range, 26-49), which classifies disease severity for patients admitted to intensive care units, validated our respiratory severity classification, with median SAPS-II of 26, 35, and 52 for No-MVS, MVS, and ECMO groups, respectively (P < .001) (see Fig E1 in this article’s Online Repository at www.jacionline.org). Patients’ SAPS-II scores were associated with mortality only in the MVS group (Fig E1).

Distinct cytokine profiles associated with COVID-19 severity
Concentrations of 12 cytokines were measured in serum from 115 patients with COVID-19 at hospital admission, and in healthy SARS-CoV-2–negative subjects (see Fig E2 in this article’s Online Repository at www.jacionline.org). As expected, PCA emphasized important overall cytokine profile differences (P < .001) between patients with COVID-19 and healthy controls, but also underlined the heterogeneity of the COVID-19 group (Fig 1 A).

To elucidate the association of serum cytokine levels with COVID-19 severity, we performed nonsupervised PCA among patients with COVID-19 only, highlighting 2 distinct cytokine combinations (Fig 1 B). Proinflammatory cytokines, including TNF-α, IL-6, IL-8, and IL-1β, as well as IL-10 and IL-22, mainly contributed to the first principal component, whereas the type-1 interferon antiviral cytokines IFN-α and IFN-β had an orthogonal contribution on the second principal component. Strikingly, these 2 distinct cytokine combinations were differentially associated with COVID-19 respiratory severity, with 96.4% of ECMO patients and 96.6% of No-MVS patients appropriately segregated by the separatrix line (P < .0001).

Taking into account only the cytokines with the greatest contribution to the principal components (Fig 1 B), 2 cytokine combination functions (fCC) were constructed: fCC-INFLAM, based on the proinflammatory cytokines TNF-α, IL-6, IL-8, and IL-10, and fCC-IFN, based on the type-1 interferons IFN-α and IFN-β (see further information in this article’s Online Repository at www.jacionline.org). These 2 cytokine combinations were distinctively...
associated with severity: \text{fcc-INFLAM} values were higher in ECMO patients ($P < .0001$; Fig 1, C), whereas \text{fcc-IFNI} values were higher in No-MVS patients ($P < .0001$; Fig 1, D), in a mutually exclusive manner.

The cytokine profiles of the MVS patients were scattered in between those of the 2 other groups (Fig 1, B), showing intermediate levels of both \text{fcc-INFLAM} and \text{fcc-IFNI} (Fig 1, C and D). Indeed, analysis by k-means clustering revealed that MVS patients could be divided into 3 subgroups ($P < .01$) with different combinations of elevated \text{fcc-INFLAM} and/or \text{fcc-IFNI} values (see Fig E3 in this article’s Online Repository at www.jacionline.org).

Repeating the same analysis with severity groups defined by SAPS-II scores showed the same association of \text{fcc-INFLAM} and \text{fcc-IFNI} with COVID-19 severity (Fig E1, B). Moreover, these results were confirmed for patients with intermediate time lapse from symptom onset (see Fig E4 in this article’s Online Repository at www.jacionline.org), for whom there was no difference in this time lapse between the groups (Table I) and no variation in cytokine levels as function of time from symptom onset (Fig E4). Logistic regression analysis taking into account all baseline factors (Table E1) confirmed that \text{fcc-INFLAM} and \text{fcc-IFNI} were the only factors remaining associated with severity in a statistically significant manner after multifactorial correction.

Furthermore, our results were confirmed in an independent validation cohort ($N = 86$). PCA of the validation cohort patients alone (see Fig E5, A, in this article’s Online Repository at www.jacionline.org), or both cohorts combined (Fig E5, B), showed again segregation of ECMO patients having higher levels of
proinflammatory cytokines and No-MVS patients having higher levels of type-I interferon response. Accordingly, the values of fcc-INFLAM and fcc-INFN were mutually exclusive, and signifi-
cantly different, between the respiratory severity groups for the validation cohort alone (Fig E5, C and E) or for both cohorts together (Fig E5, D and F).

COVID-19 mortality risk is associated with distinct cytokine profiles

To elucidate the association of serum cytokine levels at time of hospitalization with COVID-19 mortality 1 month later, we performed PCA for each oxygen support modality separately, because PCA for all patients together did not show separation between alive and deceased patients. Mortality was differentially associated with distinct cytokine combinations in each group. In ECMO patients, mortality was associated with elevated levels of proinflammatory cytokines (in particular IL-10, IL-8, IL-6, and TNF-α), as well as with decreased levels of IL-17A and IL-18 (Fig 2, C). However, in No-MVS patients, elevated levels of IFN-α and IFN-β, but not proinflammatory cytokines, were associated with mortality (Fig 2, A). Lastly, in MVS patients with SAPS-II score greater than or equal to 35 (median of the MVS group, below which only 4% of MVS patients deceased), mortality was associated with the combination of elevated levels of both proinflammatory cytokines (in particular TNF-α and IL-10) and IFN-α (Fig 2, B).

By selecting the cytokines most associated with mortality according to the principal-component factors (Fig 2, A-C), we defined an fCC for each group: fNo-MVS based on IFN-α and IFN-β for No-MVS patients (Fig 2, D), fMVS based on TNF-α, IL-10, and IFN-α for MVS patients with SAPS-II score greater than or equal to 35 (Fig 2, E), and fECMO, based on IL-10, IL-17A, and IL-18 for ECMO patients (Fig 2, F). The magnitude of each of these cytokine combinations was significantly higher in deceased as compared with alive patients in each corresponding severity group, but not in the other groups. Furthermore, regression analysis with other cofactors such as demographic characteristics, past medical history, and COVID-19–related treatment (Table E1) showed that fNo-MVS, fMVS, and fECMO were the only factors that remained significantly associated with mortality after multifactorial correction per each group accordingly.

The differential association of mortality with the different fCC identified in the initial cohort was further confirmed in an independent validation cohort (N = 86). PCA for each of the severity groups (No-MVS, MVS, and ECMO), using only the cytokines in each fCC (fNo-MVS, fMVS, and fECMO) accordingly, separated deceased and alive patients for the initial and validation cohorts together (see Fig E6, A-C, in this article’s Online Repository at www.jacionline.org). Furthermore, values of fNo-MVS, fMVS, and fECMO from both cohorts together showed a significant difference between alive and deceased patients, but only for the fCC of the corresponding group (Fig E6, D-F).

Next, we set appropriate thresholds (selected to optimize accuracy of prediction, Fig 2) for each of the fCC (fNo-MVS, fMVS, and fECMO) and generated the prediction table and scores for each group accordingly (Table II). The overall mortality of patients with COVID-19 at 1 month after admission could be predicted by measuring circulating levels of only 6 cytokines, as well as the SAPS-II score for the MVS group, with an accuracy of 88.5%, a sensitivity of 93.3%, and a specificity of 86.5% (risk ratio, 24.3; odds ratio, 89.6; P < .0001; Table II).

To investigate the robustness of the predictions, we plotted receiver-operating characteristic curves of mortality outcome comparing the 3 fCC, SAPS-II score, and age (see Fig E7 in this article’s Online Repository at www.jacionline.org), as well as all individual cytokine levels (see Fig E8 in this article’s Online Repository at www.jacionline.org) in each of the respiratory severity groups. In each group, the corresponding prediction function always represented the largest area under the curve. Moreover, to evaluate the robustness of the differential predictions, we calculated the relative sensitivity (rSens) and relative specificity (rSpec) of the corresponding function for each group and compared them with the 2 other functions (see Table E4 in this article’s Online Repository at www.jacionline.org). The combined relative predictive score (rSens × rSpec) was always larger than 1.6, indicating that each function indeed best predicted mortality for the corresponding group.

High viral load associated with mortality in No-MVS and MVS, but not in ECMO, patients

SARS-CoV-2 nucleocapsid (N)-antigen levels were measured by ELISA in 179 patients on the same day as the cytokine measurement. However, in 32 patients with sampling later than 14 days after symptom onset, antigen levels were significantly lower (P < .001). Thus, for the measurement of SARS-CoV-2 antigen, only the 147 patients sampled up to 14 days after symptom onset were considered.

Viral load was not associated with COVID-19 severity, neither as defined by oxygen support modality groups, nor by SAPS-II scores (Fig 3). However, mortality 1 month after hospitalization was associated with higher levels of antigen (Fig 3, A) in No-MVS patients (P = .002) and MVS patients (P = .008), but not in ECMO patients.

Viral load is correlated with type-I interferon response but not with inflammatory cytokines

SARS-CoV-2 antigen levels were significantly correlated with the type-I interferon cytokine combination fcc-INFN (Fig 4) in No-MVS patients (R = 0.79; P < .001) and in ECMO patients (R = 0.57; P = .002), as well as with IFN-α and IFN-β individually, but not with IFN-γ. However, in intermediate severity MVS patients, antigen levels were not correlated with those of IFN-α and IFN-β individually, nor with the fcc-INFN cytokine combination, but were correlated with IFN-γ levels instead (R = 0.45; P < .001). However, inflammatory cytokine levels, either individually or in the cytokine combination fcc-INFLAM, were not significantly correlated with viral load. Interestingly, deceased No-MVS and MVS patients (Fig 4, A and B), but not ECMO patients (Fig 4, C), had both higher levels of antigen and type-I interferons.

Association of cytokine levels and SARS-CoV-2 viral load with baseline conditions

Major baseline demographic parameters associated with COVID-19 severity or mortality (sex, age, smoking, body mass index, obesity, and overweight) were neither significantly associated with SARS-CoV-2 viral load nor with any of the cytokine levels or their combinations. Also, most baseline clinical conditions (cancer,
immunodeficiency, chronic pulmonary disease, asthma, chronic obstructive pulmonary disease, chronic liver disease, chronic neurologic disease) did not show a significant association with SARS-CoV-2 antigen levels or with any of the cytokine levels or their combinations. However, we found that chronic kidney disease was significantly \( P \leq .002 \) associated with higher SARS-CoV-2 antigen and IFN-\( \alpha \) \( (P < .001) \) levels. Patients with diabetes, cardiovascular disease, and hypertension also showed a trend for higher viral load and IFN-\( \alpha \) levels, but this was not significant when considering the occurrence of kidney disease.

Altogether, the lack of association between major baseline demographic parameters and any of the cytokine levels or their combinations further emphasizes the interest of cytokine profiling for COVID-19 patient stratification and monitoring.

**DISCUSSION**

Our finding of distinct cytokine profiles and their correlation with SARS-CoV-2 viral load sheds light on factors associated with COVID-19 severity and mortality. Critically severe patients (requiring ECMO and/or with the highest SAPS-II scores) do not have higher viral load than less severe patients, but rather exhibit higher levels of inflammatory cytokines (fcc-INFLAM) and lower type-I interferon response (fcc-IFNI). Accordingly, mortality in ECMO patients is not associated with higher viral loads or higher type-I interferon levels, but rather with the combination of high IL-10 (as well as TNF-\( \alpha \), IL-6, and IL-8) levels and low IL-17A and IL-18 levels (fECMO).

However, moderate severity patients requiring no MVS (or patients with the lowest SAPS-II scores at admission) exhibit lower inflammatory cytokine levels but a higher type-I interferon response. Mortality in this No-MVS group is strongly associated with higher viral loads and higher type-I interferon levels, but rather with the combination of high IL-10 (as well as TNF-\( \alpha \), IL-6, and IL-8) levels and low IL-17A and IL-18 levels (fECMO).

FIG 2. Distinct cytokine combinations associated with COVID-19 mortality. PCAs for each respiratory severity group: No-MVS (A), MVS(*) (B), and ECMO (C) segregate surviving vs deceased patients in association with different cytokine combinations (corresponding PC factors in the tables). Levels of the ensuing fCC from the PC factors for each group, fNo-MVS (D), fMVS (E), and fECMO (F), are depicted for surviving vs deceased patients in each respiratory severity group. ns, Nonsignificant; PC, principal component. (*)MVS with SAPS-II score greater than or equal to 35 (median of the MVS patients). *\( P < .05 \); **\( P < .01 \); ***\( P < .001 \); ****\( P < .0001 \).
**TABLE II.** Prediction of COVID-19 mortality at 1 month from admission using cytokine combinations measured at hospital admission

| Predictor | No-MVS | MVS | ECMO | All |
|-----------|--------|-----|------|-----|
| N† | 29 | 47 | 28 | 104 |
| Mortality | 24.1% | 36.2% | 21.4% | 28.9% |
| Accuracy | 86.2% | 91.5% | 85.7% | 88.5% |
| NPV | 100% | 93.3% | 100% | 97.0% |
| PPV | 63.6% | 88.2% | 60.0% | 73.7% |
| Specificity | 81.8% | 93.3% | 81.8% | 86.5% |
| Sensitivity | 100% | 88.2% | 100% | 93.3% |
| OR [95% CI] | > 29.8 [2.8-315.6] | 105 [13.4-822.1] | > 25.5 [2.4-275.7] | 89.6 [18.4-435.8] |
| RR [95% CI] | > 11.5 [1.6-81.0] | 13.2 [3.4-51.1] | > 10.8 [1.5-77.5] | 24.3 [6.1-96.5] |
| P value‡ | <.0001 | <.0001 | <.0001 | <.0001 |

NPV, Negative predictive value; OR, odds ratio; PC, principal component; PPV, positive predictive value; RR, risk ratio.

*Prediction of mortality was performed using following functions:

- **No-MVS:** \( f_{\text{NO-MVS}}(0.475 \times \log(\text{IFN-}\alpha) + 0.188 \times \log(\text{IFN-}\beta) > 0.59 \)

- **MVS:** \( f_{\text{MVS}}(0.474 \times \log(\text{TNF-}\alpha) + 0.444 \times \log(\text{IL-10}) + 0.194 \times \log(\text{IFN-}\alpha)) > 0.5 \)

- **ECMO:** \( f_{\text{ECMO}}(0.414 \times \log(\text{IL-10}) - 0.609 \times \log(\text{IL-17A}) - 0.352 \times \log(\text{IL-18})) > 0.1 \)

All: Each patient was predicted by the predictor for the corresponding oxygen support received. The coefficients are taken from corresponding PC factors in Fig 2.

†Some of the numbers are lower than those in Table I because of missing cytokine data in few patients.

‡Statistical significance of the prediction was assessed by the Fisher exact test.

**FIG 3.** SARS-CoV-2 serum viral load association with severity and mortality. **A,** SARS-CoV-2 nucleocapsid (N)-antigen levels depicted by respiratory severity group and deceased vs surviving patient per group (No-MVS: 100% ALQ in deceased vs 34.5% ALQ in surviving patients, \( P = .002; \) MVS: 86.4% ALQ in deceased vs 53.2% ALQ in surviving patients, \( P = .008; \) ECMO: 16.7% ALQ in deceased vs 47.8% ALQ in surviving patients, \( P = \text{ns} \)). **B,** SARS-II scores depicted as function of N-antigen levels per patient (\( R = 0.05; P = \text{ns} \)), with deceased vs surviving patients marked. Only patients with a sample taken at most 14 days after symptom onset are included in the analysis, because antigen levels were significantly lower in samples taken after 14 days (50% BLD), as compared with until day 14 (5.4% BLD; \( P < .0001 \)). For samples until 14 days there was no correlation of N-antigen levels with time from symptom onset and no difference between the cohorts. Ag, Antigen; ALQ, above upper limit of quantification; BLD, below limit of detection; ns, nonsignificant. *\( P < .05; \) **\( P < .01; \) ***\( P < .001; \) ****\( P < .0001. \)
Lastly, intermediate severity patients (MVS or intermediate SAPS-II scores) seem to comprise a mixed population with a large, intermediate span of both fcc-INFLAM and fcc-IFNI levels. Mortality in MVS patients is associated with higher levels of both inflammatory cytokines and type-I interferons (fccMVS) as well as higher viral loads. Indeed, we show that MVS patients can be clustered into at least 3 different subgroups in terms of their cytokine profiles (Fig E3). Thus, instead of considering the cytokine profile of each group, it may be more correct to classify severity and assess mortality risk on the basis of individual levels of the cytokine combinations identified here, together with viral load.

The association of enhanced serum cytokine levels with mortality does not necessarily imply cytokine-related toxicity. IL-6, IL-8, and TNF-α are known to have deleterious proinflammatory effects, whereas IL-10 is considered to mainly dampen inflammation, although its expression levels were found to be associated with higher mortality rates in patients requiring MVS and ECMO. These results do not point to a causal effect but to an association of the cytokine profile of each group with mortality risk on the basis of individual levels of the cytokine combinations identified here, together with viral load.

The association of enhanced serum cytokine levels with mortality does not necessarily imply cytokine-related toxicity. IL-6, IL-8, and TNF-α are known to have deleterious proinflammatory effects, whereas IL-10 is considered to mainly dampen inflammation, although its expression levels were found to be associated with higher mortality rates in patients requiring MVS and ECMO. These results do not point to a causal effect but to an association of the cytokine profile of each group with mortality risk on the basis of individual levels of the cytokine combinations identified here, together with viral load. Nevertheless, in the context of genetic inborn errors of cytokine-mediated immunity, or dependent on the presence of anticytokine autoantibodies. Nevertheless, IFN-α was detectable at high levels within the first 7 days after the onset of symptoms also in severe patients (Figs E2 and E4). Similarly, although levels of IFN-β were low in many patients with COVID-19, possibly due to a lower sensitivity of detection (see Table E3 in this article’s Online Repository at www.jacionline.org), they were nevertheless not systematically undetectable in severe patients (Fig E2), contrary to what has been previously suggested. We show that mortality in No-MVS patients is rather associated with exacerbated type-I IFN responses. Although it is possible that elevated serum interferon levels would result from downstream signaling defects in the type-I IFN pathway, previous results suggest that an actively persisting type-I IFN response is associated with immunopathology. Of note, an elevated type-I interferon response in these patients was highly correlated with elevated viral load (Fig 4), and thus could simply reflect an appropriate response to viral replication. Although we did not find evidence that an exacerbated type-I interferon response was related to cardiologic (or other) specific complications in No-MVS and MVS patients (Tables E1 and E2), it should be emphasized that mortality in these groups was associated with the highest type-I interferon levels.

**FIG 4.** Correlation between SARS-CoV-2 serum viral load and cytokine levels. The fCC values for fcc-IFNI comprising type-I interferons IFN-α, and IFN-β (A-C) and fcc-INFLAM comprising the inflammatory cytokines TNF-α, IL-10, IL-6, and IL-8 (D-F) are plotted as function of SARS-CoV-2 nucleocapsid (N)-antigen levels for each of the respiratory severity groups. Only patients with a sample taken at most 14 days after symptom onset are included in the analysis (see Fig 3). Ag, Antigen; ALQ, above upper limit of quantification; BLD, below limit of detection; N.S., nonsignificant.
Therapeutic approaches in patients with COVID-19 targeting only 1 type of cytokine, such as IL-6 or GM-CSF, have been reported not to be effective for preventing death.\(^3\),\(^4\),\(^2\) Moreover, targeting IL-1β could even be harmful, because an excess of premature deaths was recently reported in patients with COVID-19 receiving an IL-1 receptor antagonist.\(^5\),\(^6\) Indeed, we found no association between GM-CSF or IL-1β and mortality. Furthermore, IL-6 was only mildly associated with mortality in ECMO patients, as was TNF-α, arguing that the use of antagonists targeting only these cytokines might not be best suited for all patients with life-threatening COVID-19, contrasting with a recent suggestion.\(^7\),\(^8\)

Our findings could also explain why the administration of glucocorticoids, in particular dexamethasone, which decreases blood levels of many cytokines, was successful in both patients receiving invasive mechanical ventilation (MVS) and those receiving oxygen without invasive mechanical ventilation, corresponding to part of No-MVS patients.\(^9\),\(^10\) Because mortality in these patients was found to be strongly associated with high levels of type-I IFNs, the modulation of secretion and/or activity of the latter cytokines could be related to corticosteroid efficacy.\(^11\)

The present study shows that cytokine profiling may have clinical implications for improved personalized treatment. For example, no-MVS patients do not present with enhanced levels of circulating inflammatory cytokines, such as IL-6 or TNF-α, thereby arguing that treatment with antagonists of the latter cytokines is not suitable for this group of patients. Moreover, profiling type-I IFN and anti-IFN antibodies in the serum of patients with COVID-19 may contribute to the selection of those who are most likely to benefit from IFN-β therapy.\(^12\)

Associations of cytokine combinations with COVID-19 severity and mortality were confirmed in an independent, second pandemic wave validation cohort. It should be noted that these patients had all received corticosteroids at the time of sampling (in contrast to the patients of the initial cohort). The observed associations hold both with and without corticosteroid treatment. The mortality prediction table presented here was calculated only on the basis of initial cohort results, because those were measured at day of hospitalization, unlike the validation cohort. Receiver-operating characteristic curve analysis and the 95% CI of the odds ratios show the robustness of the mortality predictions per severity group. Altogether, on the basis of 6 cytokines measured at day of hospitalization, we obtained a highly accurate (88.5%) mortality prediction with 93.3% sensitivity and 86.5% specificity (positive predictive value = 73.7% and negative predictive value = 97%). A prediction for survival would miss very few (6.7%) patients who actually deceased, and of those predicted to decease only 26.3% would actually survive, constituting a useful guidance of early specific treatment for those predicted to decease. The odds ratio (89.6) and relative ratio (24.3) obtained here are higher than those previously reported for individual inflammatory cytokine levels with a maximum hazard ratio of 4.2,\(^7\) genetic markers with maximum odds ratio of 2.5,\(^13\) or chest radiography with maximum accuracy of 74%.\(^14\) Our results emphasize the importance of cytokine combination profiling in assessing severity and mortality.

Conclusions

Our results concur with the notion of an overproduction of a distinct set of cytokines following SARS-CoV-2 infection, although not as a unique cytokine storm, but as the occurrence of distinct cytokine profiles associated with respiratory severity in patients with COVID-19. Furthermore, mortality in the different severity groups was also found associated with distinct cytokine production profiles. We therefore advocate improved personalized patient management through cytokine profiling.

We thank the physicians and nurses from the clinical departments of Pitié-Salpêtrière Hospital who made this study possible, all members from the Cimi-COVID-19 Consortium, and particularly Lucille Adam, Olivia Bonduelle, Armanda Casrouge, Laetitia Claë, Audrey Mohr, and Pierre Rosenbaum, for their participation in sample processing and biobanking, as well as Laura Wakselman and Linda Gimeno, from the Clinical Research Unit (URC) of Pitié-Salpêtrière hospital, for help with regulatory and ethical compliance.

Key messages

- COVID-19 severity is associated with distinct cytokine profiles, whereas measurement of 6 cytokines at hospital admission predicts mortality.
- SARS-CoV-2 antigenemia, associated with mortality in moderate severity patients, correlates with levels of type-I interferon, but not with other proinflammatory cytokines.
- These results call for personalized COVID-19 management based on a combined cytokine/viral load profiling.

REFERENCES

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 2020;395:497-506.
2. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020;181:894-904.e9.
3. Schmidt M, Hajage D, Lebreton G, Morel A, Viroigt G, Levy D, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. Lancet Respir Med 2020;8:1121-31.
4. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020;368:473-4.
5. Chen J, Subbarao K. The immunobiology of SARS*. Ann Rev Immunol 2007;25:443-72.
6. The WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020;324:1330-41.
7. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-63.
8. Hingrat QL, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y, et al. Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives [published online ahead of print December 8, 2020]. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2020.11.025.
9. Jankevic R, Kullberg MC, Feng CG, Goldszmid RS, Collazo CM, Wilson M, et al. Conventional T-bet (+) Foxp3(–) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med 2007;204:273-83.
10. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic muco-cutaneous candidiasis in humans with inborn errors of interferulin-17 immunity. Science 2011;332:65-8.
11. Liu B, Mori I, Hossain MJ, Dong L, Takeda K, Kimura Y. Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. J Gen Virol 2004;85:423-8.
12. Oldham RR. Toxic effects of interferon. Science 1983;219:902.
13. Teragawa H, Hondo T, Amano H, Kimura Y, Hino F, Ohbayashi M. Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. J Gen Virol 2004;85:423-8.
14. Oldham RR. Toxic effects of interferon. Science 1983;219:902.
consequences of an unhealthy western lifestyle. Front Endocrinol (Lausanne) 2020;11:58-287.

15. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Möller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020;181:1036-43.e9.

16. Trouillet-Assant S, Viel S, Gaymard A, Pons S, Richard JC, Perret M, et al. Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol 2020;146:206-8.e2.

17. Zhang Q, Bastard P, Liu Z, Pen JL, Moncada-Velez M, Moncada-Velez M, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020;370:eabd4570.

18. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020;370:423.

19. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020;369:718-24.

20. Notarangelo LD, Bacchetta R, Casanova JL, Su HC. Human inborn errors of immunity: an expanding universe. Sci Immunol 2020;5:eabb1662.

21. Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020;181:1016-35.e19.

22. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 2016;19:181-93.

23. De Luca G, Cavalli G, Campochiaro C, Della-Torre E, Angelillo P, Tomelleri A, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol 2020;2:e465-73.

24. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020;383:2333-44.

25. The CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med 2021;9:295-304.

26. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020;26:1636-43.

27. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mathew M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med 2021;384:693-704.

28. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.

29. Dorgham K, Neumann AU, Decavele M, Layt C-E, Yssel H, Gorochov G. Considering personalized interferon-β therapy for COVID-19. Antimicrob Agents Chemother 2021;65:AAC.00065-21.

30. Pairo-Castinea E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in Covid-19. Nature 2021;591:92-8.

31. Kwon YJ, Toussie D, Finkelstein M, Cedillo MA, Maron SZ, Manna S, et al. Combining initial radiographs and clinical variables improves deep learning prognostication of patients with COVID-19 from the emergency department [published online ahead of print December 16, 2020]. Radiol Artif Intell. https://doi.org/10.1148/ryai.2020200098.